 |
 |
根據(jù)ROC曲線確定的界值，galectin-3、CEA及CA199診斷胰腺癌的陽性率分別為33.3%、50.0%及63.3%。3項(xiàng)指標(biāo)中g(shù)alectin-3雖然敏感性較低，但其有較高的特異性，CEA及CA199對(duì)胰腺癌的診斷敏感性相差不多，但CA199診斷特異性要略優(yōu)于CEA。3項(xiàng)指標(biāo)都存在診斷敏感性或診斷特異性不太高的缺陷，因此單獨(dú)檢測(cè)galectin-3、CEA及CA199診斷胰腺癌均有局限性。聯(lián)合檢測(cè)能夠在一定程度上彌補(bǔ)單一指標(biāo)檢測(cè)的不足，三者對(duì)胰腺癌的診斷存在互補(bǔ)價(jià)值，二項(xiàng)聯(lián)合檢測(cè)組合以galectin-3加CA199最優(yōu)，既可提高診斷敏感性，又不會(huì)明顯降低特異性。3項(xiàng)聯(lián)合檢測(cè)雖會(huì)使診斷特異性有所下降，可明顯提高診斷敏感性，對(duì)胰腺癌的篩查具有重要臨床價(jià)值。Galectin-3作為對(duì)傳統(tǒng)胰腺癌標(biāo)志物的補(bǔ)充對(duì)胰腺癌早期診斷及鑒別診斷具有十分重要的意義，galectin-3有可能成為胰腺癌的重要血清標(biāo)志物之一。
因本實(shí)驗(yàn)中g(shù)alectin-3的檢測(cè)為雙抗體夾心生物素-親和素ELISA法，其檢測(cè)敏感性不太高，不能檢測(cè)出微量的galectin-3，可能是導(dǎo)致胰腺癌陽性率不太高的原因之一。今后我們將研究開發(fā)更敏感的檢測(cè)方法，進(jìn)一步擴(kuò)大病例數(shù)，深入研究galectin-3作為胰腺癌標(biāo)志物的臨床意義。
【參考文獻(xiàn)】
[1] Coli A, Bigotti G, Zucchetti F, et al.Galectin-3, a marker of well-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia[J].Histopathology, 2002， 40(1):80-87醫(yī).學(xué)全.在.線網(wǎng)站bhskgw.cn.
[2] Martins L,Matsuo SE,Ebina KN, et al.Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors[J]. J Clin Endocrinol Metab, 2002, 87(10):4806-4810.
[3] Sakakura C, Hagiwara A, Nakanishi M,et al. Differential gene expression profiles of gastric cancer cells established from primary tumour and malignant ascites[J]. Br J Cancer, 2002, 87(10):1153-1161.
[4] Chen JH, Ni RZ, Xiao MB,et al.Comparative proteomic analysis of differentially expressed proteins in human pancreatic cancer tissue[J]. Hepatobiliary Pancreat Dis Int, 2009, 8(2):193-200.
[5] Ulmer TA, Keeler V, Loh L , et al. Tumor-associated antigen 90K/Mac-2-binding protein: possible role in colon cancer[J]. J Cell Biochem, 2006, 98(5):1351-1366.
[6] Yang ZM, Wu XT, He T, et al. Expression of Galectin-3 mRNA in gastric cancer with peritoneal metastasis[J]. Sichuan DaXue Xue Bao Yi Xue Ban, 2006, 37(1):105-108.
[7] Okada K, Shimura T, Suehiro T, et al. Reduced Galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer[J]. Anticancer Res, 2006, 26(2B):1369-1376.
[8] Jiang HB, Xu M, Wang XP. Pancreatic stellate cells promote proliferation and invasiveness of human pancreatic cancer cells via galectin-3[J]. World J Gastroenterol, 2008, 14(13):2023-2028.
[9] Shimamura T, Sakamoto M, Ino Y, et al. Clinicopatho-logical significance of galectin-3 expression in ductal adenocarcinoma of the pancreas[J]. Clin Cancer Res, 2002, 8(8):2570-2575.
